EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway

Tetsuzo Tauchi, Shota Moriya iD, Seiichi Okabe, Hiromi Kazama, Keisuke Miyazawa, Naoharu Takano iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0307662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Tetsuzo Tauchi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shinyurigaoka General Hospital, Asou-ku, Kawasaki, Kanagawa, Japan. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Proto-Oncogene Proteins c-bcl-2, Sulfonamides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Promising outcomes have been reported in elder patients with acute myeloid leukemia (AML) using combined therapy of venetoclax (VEN) and azacytidine (AZA) in recent years. However, approximately one-third of patients appear to be refractory to this therapy. Vitamin K2 (VK2) shows apoptosis-inducing activity in AML cells, and daily oral VK2 (menaquinone-4, Glakay R ) has been approved for patients with osteoporosis in Japan. We observed a high response rate to AZA plus VEN therapy, with no 8-week mortality in the newly diagnosed AML patients consuming daily VK2 in our hospital. The median age of the patients was 75.9 years (range 66–84) with high-risk features. Patients received AZA 75 mg/m 2 on D1-7, VEN 400 mg on D1-28, and daily VK2 45 mg. The CR/CRi ratio was 94.7% (18/19), with a CR rate of 79%. Complete cytogenetic CR was achieved in 15 of 19 (79%) patients, and MRD negativity in 2 of 15 (13%) evaluable CR patients. Owing to the extremely high response rate in clinical settings, we further attempted to investigate the underlying mechanisms. The combination of VK2 and VEN synergistically induced apoptosis in all five AML cell lines tested. VK2, but not VEN, induced mitochondrial reactive oxygen species (ROS), leading to the transcriptional upregulation of NOXA, followed by MCL-1 repression. ROS scavengers repressed VK2 induced-NOXA expression and led to the cancellation of pronounced apoptosis and the downregulation of MCL-1 by VK2 plus VEN. Additionally, knockdown and knockout of NOXA resulted in abrogation of the MCL-1 repression as well as enhanced cytotoxicity by the two-drug combination, indicating that VK2 suppresses MCL-1 via ROS-mediated NOXA induction. These data suggest that the dual inhibition of BCL-2 by VEN and MCL-1 by VK2 is responsible for the remarkable clinical outcomes in our patients. Therefore, large-scale clinical trials are required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteBridged Bicyclo Compounds, HeterocyclicProto-Oncogene Proteins c-bcl-2SulfonamidesVitamin K 2Myeloid Cell Leukemia Sequence 1 ProteinApoptosisHumansAgedFemaleMaleAged, 80 and overCell Line, TumorSignal TransductionDrug SynergismAntineoplastic Combined Chemotherapy ProtocolsReactive Oxygen SpeciesAzacitidineAntineoplastic Agents

Substanzen

Bridged Bicyclo Compounds, HeterocyclicProto-Oncogene Proteins c-bcl-2venetoclaxSulfonamidesVitamin K 2Myeloid Cell Leukemia Sequence 1 ProteinPMAIP1 protein, humanMCL1 protein, humanReactive Oxygen SpeciesAzacitidine

Autor:innen und Institutionen

  • Shinyurigaoka General Hospital, Asou-ku, Kawasaki, Kanagawa, Japan.
  • Department of Biochemistry, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.
  • Department of Hematology, Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

ORCID-Profile: Shota Moriya, Naoharu Takano

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Tauchi, T., Moriya, S., Okabe, S., Kazama, H., Miyazawa, K., & Takano, N. (2024). Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway. PLOS ONE. https://doi.org/10.1371/journal.pone.0307662

Vancouver

Tauchi T, Moriya S, Okabe S, Kazama H, Miyazawa K, Takano N. Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway. PLOS ONE. 2024. doi:10.1371/journal.pone.0307662

BibTeX
@article{Tauchi2024,
  author = {Tauchi, Tetsuzo and Moriya, Shota and Okabe, Seiichi and Kazama, Hiromi and Miyazawa, Keisuke and Takano, Naoharu},
  title = {Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0307662}
}
Kostenlos starten →